BRIEF published on 02/12/2025 at 07:35, 1 year 2 months ago GenSight Biologics Reports Positive Five-Year Outcomes for LUMEVOQ® Gene Therapy Gene Therapy LUMEVOQ® Visual Acuity Safety Profile REFLECT Study
PRESS RELEASE published on 02/12/2025 at 07:30, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics reports 5-year efficacy and safety results for LUMEVOQ® gene therapy in REFLECT study with sustained visual improvement and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity REFLECT Study
BRIEF published on 01/23/2025 at 18:50, 1 year 3 months ago GenSight Biologics: Financial Report and Outlook GenSight Biologics Capital Increases LUMEVOQ® Compassionate Access Treasury 2024
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year 3 months ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
BRIEF published on 01/15/2025 at 07:35, 1 year 3 months ago GenSight Biologics Reports Long-Term Results for LUMEVOQ® Gene Therapy GenSight Biologics LUMEVOQ® Visual Acuity Leber's Hereditary Optic Neuropathy
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 3 months ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 1 year 3 months ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
BRIEF published on 12/24/2024 at 20:51, 1 year 4 months ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 4 months ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
BRIEF published on 11/13/2024 at 07:35, 1 year 5 months ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
Published on 05/01/2026 at 00:45, 11 minutes ago Inventus Announces Closing of $2.5 Million Non-Brokered Flow-Through Financing
Published on 04/30/2026 at 23:55, 1 hour 1 minute ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended March 31, 2026
Published on 04/30/2026 at 23:05, 1 hour 51 minutes ago AIP Realty Trust Announces Year End 2025 Results
Published on 04/30/2026 at 21:00, 3 hours 56 minutes ago Datavault AI Schedules Conference Call to Discuss First Quarter 2026 Financial Results on Friday, May 15, 2026
Published on 04/30/2026 at 23:39, 1 hour 17 minutes ago Anemoi International Ltd: Final Results For Year Ended 31 December 2025
Published on 04/30/2026 at 22:35, 2 hours 21 minutes ago Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma
Published on 04/30/2026 at 22:04, 2 hours 52 minutes ago Interim individual financial statements for the period ending on March 31, 2026 of Sirma Group Holding JSC
Published on 04/30/2026 at 19:00, 5 hours 55 minutes ago DOUGLAS Group grows sales in Q2 and updates full-year guidance on adjusted EBITDA
Published on 04/30/2026 at 19:00, 5 hours 56 minutes ago BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
Published on 04/30/2026 at 20:00, 4 hours 55 minutes ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 5 hours 40 minutes ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 5 hours 56 minutes ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 6 hours 46 minutes ago Minutes of the Combined General Meeting held on April 30, 2026
